These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17047431)

  • 21. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.
    Chaudhry AS; Kochhar R; Kohli KK
    Indian J Med Res; 2008 Jun; 127(6):521-30. PubMed ID: 18765869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Lee SB; Park SJ; Ryu JK; Lee JK; Kim HJ; Bae JS; Jung HS; Park SM
    Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYP2C19 polymorphism and proton pump inhibitors.
    Klotz U; Schwab M; Treiber G
    Basic Clin Pharmacol Toxicol; 2004 Jul; 95(1):2-8. PubMed ID: 15245569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
    Morozov SV; Tsodikova OM; Isakov VA; Gushchin AE; Shipulin GA
    Eksp Klin Gastroenterol; 2003; (6):58-63, 154. PubMed ID: 15065530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability.
    Kita T; Tanigawara Y; Aoyama N; Hohda T; Saijoh Y; Komada F; Sakaeda T; Okumura K; Sakai T; Kasuga M
    Pharm Res; 2001 May; 18(5):615-21. PubMed ID: 11465416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Importance of CYP2C19 genetic polymorphism in the eradication of Helicobacter pylori in north Indians.
    Chaudhry AS; Kochhar R; Kohli KK
    Indian J Med Res; 2009 Oct; 130(4):437-43. PubMed ID: 19942749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
    Clin Pharmacol Ther; 2006 Nov; 80(5):539-48. PubMed ID: 17112810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.
    Chwiesko A; Charkiewicz R; Niklinski J; Luczaj W; Skrzydlewska E; Milewski R; Baniukiewicz A; Wroblewski E; Rosolowski M; Dabrowski A
    J Dig Dis; 2016 Sep; 17(9):588-599. PubMed ID: 27518195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study.
    Furuta K; Adachi K; Ohara S; Morita T; Tanimura T; Koshino K; Kinoshita Y
    J Int Med Res; 2010; 38(4):1473-83. PubMed ID: 20926021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
    Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers.
    Shimatani T; Moriwaki M; Xu J; Tazuma S; Inoue M
    Dig Liver Dis; 2006 Nov; 38(11):802-8. PubMed ID: 16843075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.
    Furuta T; Ohashi K; Kosuge K; Zhao XJ; Takashima M; Kimura M; Nishimoto M; Hanai H; Kaneko E; Ishizaki T
    Clin Pharmacol Ther; 1999 May; 65(5):552-61. PubMed ID: 10340921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers.
    Wang Y; Zhang H; Meng L; Wang M; Yuan H; Ou N; Zhang H; Li Z; Shi R
    Eur J Clin Pharmacol; 2010 Jun; 66(6):563-9. PubMed ID: 20414645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
    Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
    Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
    Oh JH; Dong MS; Choi MG; Yoo HW; Lee SB; Park YI; Chung IS
    J Gastroenterol Hepatol; 2009 Feb; 24(2):294-8. PubMed ID: 18823430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation.
    Yamano HO; Matsushita HO; Yanagiwara S
    J Gastroenterol Hepatol; 2008 Apr; 23(4):534-40. PubMed ID: 17725594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy.
    Peters FT; Kuipers EJ; Ganesh S; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
    Aliment Pharmacol Ther; 1999 Jul; 13(7):921-6. PubMed ID: 10383527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
    Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ
    Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.